





Bosnia and Herzegovina Linear; Intro range Linear; No intro range 1.00 0.75 vaccine 0.50 BCG DTP3 HepB 0.25 HepB_BD Hib3 Coverage Coverage HPV JΕ Non-linear; Intro range Non-linear; No intro range MCV1 1.00 MCV2 MenA PCV3 0.75 RCV2 Rota Rubella 0.50 YF 0.25 0.00


Year


























































Democratic Republic of the Congo Linear; Intro range Linear; No intro range 1.00 0.75 vaccine 0.50 **BCG** DTP3 HepB 0.25 HepB_BD Hib3 Coverage Coverage 0.00 HPV JΕ Non-linear; Intro range Non-linear; No intro range MCV1 MCV2 MenA PCV3 0.75 RCV2 Rota Rubella 0.50 ΥF 0.25 0.00 Year
































































Guinea-Bissau Linear; Intro range Linear; No intro range 1.00 0.75 vaccine 0.50 BCG DTP3 HepB 0.25 HepB_BD Hib3 Coverage Coverage HPV JΕ Non-linear; Intro range Non-linear; No intro range MCV1 1.00 MCV2 MenA PCV3 0.75 RCV2 Rota Rubella 0.50 YF 0.25 0.00 Year























































Lao People's Democratic Republic Linear; Intro range Linear; No intro range 1.00 0.75 vaccine 0.50 **BCG** DTP3 HepB 0.25 HepB_BD Hib3 Coverage Coverage 0.00 HPV JΕ Non-linear; Intro range Non-linear; No intro range MCV1 MCV2 MenA PCV3 0.75 RCV2 Rota Rubella 0.50 ΥF 0.25 0.00 Year





























































































































Saint Vincent and the Grenadines Linear; Intro range Linear; No intro range 1.00 0.75 vaccine 0.50 BCG DTP3 HepB 0.25 HepB_BD Hib3 HPV Coverage Coverage JΕ Non-linear; Intro range Non-linear; No intro range MCV1 1.00 MCV2 MenA PCV3 0.75 RCV2 Rota Rubella 0.50 YF 0.25 0.00 Year

